赢8娱乐糖果配对游戏-官方网站[welcome]


+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

PSA response to secondary androgen deprivation following failed treatment of metastatic prostate cancer with the antiandrogen casodex



PSA response to secondary androgen deprivation following failed treatment of metastatic prostate cancer with the antiandrogen casodex



Urologic Oncology 1(2): 64-66



Casodex? (ZENECA Limited) is a new antiandrogen presently under investigation for the treatment of metastatic prostate cancer. This study was designed to analyze response and possible prognostic significance of prostate specific antigen (PSA) monitoring when secondary androgen deprivation is administered at disease progression after treatment with a once-daily dose of Casodex 50 mg. Of the 31 patients receiving Casodex, 28 progressed and were treated with either orchiectomy or a luteinizing hormone releasing hormone agonist. Of the 23 patients who had follow-up PSA determinations, 19 (83%) showed a subsequent PSA decline. Median survival following secondary therapy was 22 months in the 14 patients whose decline was 50% or greater; survival was 17 months in the 9 patients whose PSA either rose or declined by less than 50% (p = 0.1711). In this small study, reduction in PSA with medical or surgical castration following initial monotherapy with Casodex, 50 mg suggests incomplete androgen blockade with this dose of Casodex. While a trend suggesting a predictive value to PSA decline following secondary androgen deprivation was demonstrated, the change was not statistically significant.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 054841827

Download citation: RISBibTeXText

PMID: 21224093

DOI: 10.1016/1078-1439(95)00011-6


Related references

Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade. European Urology 31(2): 216-219, 1997

Feasibility study for the treatment of metastatic prostate cancer with the radioactive antiandrogen I-125-bicalutamide (=I-125-casodex). International Journal of Radiation Oncology*biology*physics 48(3-Supp-S1): 316-0, 2000

Androgen Receptor Gene Amplificationin a Recurrent Prostate Cancer afterMonotherapy with the NonsteroidalPotent Antiandrogen Casodex(Bicalutamide) with a SubsequentFavorable Response to MaximalAndrogen Blockade. European Urology 31(2): 216-219, 1997

Pathological and morphometric assessment of testicular parameters in patients with metastatic prostate cancer following treatment with either the antiandrogen Casodex (ZM176334) or bilateral orchidectomy. Urological Research 22(3): 191-195, 1994

Failure of chemotherapy to prolong life in patients with metastatic prostate cancer who have failed androgen deprivation. Urology 31(1): 38-40, 1988

Randomised study of Casodex 50 MG monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. The Scandinavian Casodex Cooperative Group. Scandinavian Journal of Urology and Nephrology 30(2): 93-98, 1996

Once daily treatment with the nonsteroidal antiandrogen casodex for advanced prostate cancer. Journal of Urology 143(4 Suppl.): 308A, 1990

Casodex (bicalutamide): overview of a new antiandrogen developed for the treatment of prostate cancer. European Urology 31(Suppl. 2): 30-39, 1997

Clinical trials with the nonsteroidal antiandrogen casodex in the treatment of advanced prostate cancer. Cancer Investigation 9(3): 384, 1991

Efficacy and safety of the nonsteroidal antiandrogen casodex in the treatment of advanced prostate cancer. Journal of Urology 141(4 Part 2): 346A, 1989

Prolonged response to nilutamide in a patient with stage D0.5 prostate cancer who previously failed androgen deprivation therapy. American Journal of Therapeutics 12(2): 172-174, 2005

Androgen receptor localisation and turnover in human prostate epithelium treated with the antiandrogen, casodex. Journal of Molecular Endocrinology 24(3): 339-351, 2000

Predictors of poor response to secondary alternative antiandrogen therapy with flutamide in metastatic castration-resistant prostate cancer. Japanese Journal of Clinical Oncology 2016:, 2016

SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. Journal of Clinical Oncology 33(14): 1601-1608, 2015

Tolerability and quality of life aspects with the anti-androgen Casodex (ICI 176,334) as monotherapy for prostate cancer. International Casodex Investigators. European Urology 26(Suppl. 1): 15-19, 1994





赢8娱乐糖果配对游戏